DE69131992T2 - Papillomavirusuntereinheit-impfstoff - Google Patents

Papillomavirusuntereinheit-impfstoff

Info

Publication number
DE69131992T2
DE69131992T2 DE69131992T DE69131992T DE69131992T2 DE 69131992 T2 DE69131992 T2 DE 69131992T2 DE 69131992 T DE69131992 T DE 69131992T DE 69131992 T DE69131992 T DE 69131992T DE 69131992 T2 DE69131992 T2 DE 69131992T2
Authority
DE
Germany
Prior art keywords
papillomavirus
sequence
vaccine
drahyni
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131992T
Other languages
English (en)
Other versions
DE69131992D1 (de
Inventor
Robert Tindle
Germain Fermando
Ian Frazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
CSL Ltd
Original Assignee
University of Queensland UQ
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, CSL Ltd filed Critical University of Queensland UQ
Publication of DE69131992D1 publication Critical patent/DE69131992D1/de
Application granted granted Critical
Publication of DE69131992T2 publication Critical patent/DE69131992T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69131992T 1990-12-12 1991-12-12 Papillomavirusuntereinheit-impfstoff Expired - Lifetime DE69131992T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK387690 1990-12-12
PCT/AU1991/000575 WO1992010513A1 (en) 1990-12-12 1991-12-12 Subunit papillomavirus vaccine and peptides for use therein

Publications (2)

Publication Number Publication Date
DE69131992D1 DE69131992D1 (de) 2000-03-23
DE69131992T2 true DE69131992T2 (de) 2000-06-29

Family

ID=3775135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131992T Expired - Lifetime DE69131992T2 (de) 1990-12-12 1991-12-12 Papillomavirusuntereinheit-impfstoff

Country Status (7)

Country Link
EP (1) EP0561885B1 (de)
JP (1) JPH06503559A (de)
KR (1) KR100252371B1 (de)
AT (1) ATE189818T1 (de)
CA (1) CA2097916C (de)
DE (1) DE69131992T2 (de)
WO (1) WO1992010513A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
EP1288292A1 (de) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
US7202034B2 (en) 2000-12-08 2007-04-10 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
JPWO2002100889A1 (ja) * 2001-06-08 2004-09-24 麒麟麦酒株式会社 ヒトパピローマウイルスｅ７抗原の新規エピトープおよびそのエピトープにより活性化されたｃｄ４陽性ｔ細胞
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
EP2197497B1 (de) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Verwendung von liposomen in einem träger mit einer kontinuierlichen hydrophoben phase zur abgabe von polynucleotiden in vivo
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
WO2013049941A1 (en) 2011-10-06 2013-04-11 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
KR910016343A (ko) * 1990-03-20 1991-11-05 스타인, 부그 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
PT523391E (pt) * 1991-07-13 2003-08-29 Dade Behring Marburg Gmbh Utilizacao dos peptidos derivados dos genes hpv-16 e6 e e7 para fins de diagnostico

Also Published As

Publication number Publication date
CA2097916A1 (en) 1992-06-13
DE69131992D1 (de) 2000-03-23
JPH06503559A (ja) 1994-04-21
ATE189818T1 (de) 2000-03-15
WO1992010513A1 (en) 1992-06-25
EP0561885B1 (de) 2000-02-16
KR100252371B1 (ko) 2000-05-01
EP0561885A1 (de) 1993-09-29
CA2097916C (en) 2001-08-21
EP0561885A4 (en) 1994-09-21

Similar Documents

Publication Publication Date Title
DE69131992D1 (de) Papillomavirusuntereinheit-impfstoff
DK0593754T3 (da) Peptider fra humant papillomavirus til anvendelse i præparater til induktion af humant T-celle respons
BR9814487A (pt) "vacina"
FR07C0073I2 (fr) Vaccin contre le papillomavirus
CA2074153A1 (en) Seroreactive regions on hpv 16 proteins e1 and e2
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
MA24638A1 (fr) Vaccin
DE69206631D1 (de) Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
DE59608274D1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
HUP0303942A2 (hu) Új vakcinakészítmények
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
ATE193974T1 (de) Chlamydia impfstoffen
HUP0202770A2 (hu) Humán papillómavírus oltóanyag
DK0762895T3 (da) Syntetisk vaccine til beskyttelse mod infektion med human immundefektvirus
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
WO1999024466A3 (en) Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition